Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients

• Autori principali: Cong Wang (Autore), Fang Chen (Autore), Yichen Liu (Autore), Qingqing Xu (Autore), Liang Guo (Autore), Xiaoqing Zhang (Autore), Yunfeng Ruan (Autore), Ye Shi (Autore), Lu Shen (Autore), Mo Li (Autore), Huihui Du (Autore), Xiaofang Sun (Autore), Jingsong Ma (Autore), Lin He (Autore), Shengying Qin (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2018-04-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Patients treated with erlotinib experience different drug responses. The effect of germline mutations on therapeutic r...